Dr Karim Fizazi speaks to ecancer about the TALAPRO-1 phase II study of talazoparib (TALA) in patients with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC). The results from this study were presented at ASCO GU 2021.
Initially he talks about what the TALAPRO study is about and then moves on to explain the updates from this study that were presented at ASCO GU 2021 and what it means for patients with metastatic castration resistant prostate cancer.
He then discusses the efficacy of talazoparib in patients with DNA damage repair alteration and mCRPC. Dr Fizazi also explains how the results from this study can impact the future treatment of mCRPC.
He further explains the screening criteria used in this study.
In the end, he talks about some other emerging therapies for treating mCRPC.
This programme has been supported by an unrestricted educational grant from Pfizer.